Immunic (IMUX) Competitors $0.99 -0.29 (-22.65%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMUX vs. RVNC, MAZE, MREO, ZYBT, ZVRA, ETON, RAPP, AMLX, KMDA, and ALTShould you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Revance Therapeutics (RVNC), Maze Therapeutics (MAZE), Mereo BioPharma Group (MREO), Zhengye Biotechnology (ZYBT), Zevra Therapeutics (ZVRA), Eton Pharmaceuticals (ETON), Rapport Therapeutics (RAPP), Amylyx Pharmaceuticals (AMLX), Kamada (KMDA), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry. Immunic vs. Revance Therapeutics Maze Therapeutics Mereo BioPharma Group Zhengye Biotechnology Zevra Therapeutics Eton Pharmaceuticals Rapport Therapeutics Amylyx Pharmaceuticals Kamada Altimmune Immunic (NASDAQ:IMUX) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Does the MarketBeat Community believe in IMUX or RVNC? Revance Therapeutics received 291 more outperform votes than Immunic when rated by MarketBeat users. However, 65.09% of users gave Immunic an outperform vote while only 59.67% of users gave Revance Therapeutics an outperform vote. CompanyUnderperformOutperformImmunicOutperform Votes11065.09% Underperform Votes5934.91% Revance TherapeuticsOutperform Votes40159.67% Underperform Votes27140.33% Which has preferable earnings & valuation, IMUX or RVNC? Immunic has higher earnings, but lower revenue than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$93.61M-$1.23-0.80Revance Therapeutics$234.04M1.63-$323.99M-$1.93-1.89 Is IMUX or RVNC more profitable? Immunic has a net margin of 0.00% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -169.55% -118.96% Revance Therapeutics -74.67%N/A -37.22% Does the media prefer IMUX or RVNC? In the previous week, Immunic had 8 more articles in the media than Revance Therapeutics. MarketBeat recorded 8 mentions for Immunic and 0 mentions for Revance Therapeutics. Immunic's average media sentiment score of 0.91 beat Revance Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the media. Company Overall Sentiment Immunic Positive Revance Therapeutics Neutral Do institutionals and insiders hold more shares of IMUX or RVNC? 51.8% of Immunic shares are held by institutional investors. Comparatively, 97.7% of Revance Therapeutics shares are held by institutional investors. 3.0% of Immunic shares are held by insiders. Comparatively, 5.1% of Revance Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, IMUX or RVNC? Immunic has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Do analysts prefer IMUX or RVNC? Immunic presently has a consensus target price of $13.20, suggesting a potential upside of 1,233.20%. Revance Therapeutics has a consensus target price of $8.39, suggesting a potential upside of 129.75%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Revance Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Revance Therapeutics 0 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.11 SummaryImmunic beats Revance Therapeutics on 12 of the 18 factors compared between the two stocks. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMUX vs. The Competition Export to ExcelMetricImmunicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.87M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.807.4422.4818.48Price / SalesN/A242.70395.10103.59Price / CashN/A65.8538.1834.62Price / Book1.556.516.774.25Net Income-$93.61M$143.21M$3.22B$248.23M7 Day Performance-13.15%1.98%1.50%0.89%1 Month Performance-7.03%6.89%4.01%3.53%1 Year Performance-23.84%-2.52%16.16%5.08% Immunic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMUXImmunic2.4713 of 5 stars$0.99-22.6%$13.20+1,233.2%-21.4%$94.87MN/A-0.8070Analyst ForecastNews CoverageGap DownHigh Trading VolumeRVNCRevance Therapeutics2.46 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Upcoming EarningsMAZEMaze TherapeuticsN/A$8.69+3.3%$25.67+195.4%N/A$380.59M$167.50M0.00121MREOMereo BioPharma Group2.3344 of 5 stars$2.39+3.9%$7.71+222.8%-15.1%$380.01M$1M-39.8340Positive NewsZYBTZhengye BiotechnologyN/A$8.00-20.5%N/AN/A$377.33M$189.75M0.00278Gap DownHigh Trading VolumeZVRAZevra Therapeutics2.7749 of 5 stars$6.92-3.2%$22.29+222.0%+60.0%$374.48M$23.61M-3.5120Upcoming EarningsNews CoveragePositive NewsETONEton Pharmaceuticals2.3485 of 5 stars$13.96-2.6%$27.67+98.2%+381.4%$374.38M$39.01M-63.4520Upcoming EarningsAnalyst RevisionNews CoverageGap UpRAPPRapport Therapeutics2.442 of 5 stars$10.22+0.7%$32.67+219.6%N/A$372.99MN/A-0.74N/AAMLXAmylyx Pharmaceuticals3.0347 of 5 stars$4.19+5.3%$8.00+90.9%+182.3%$371.24M$87.37M-1.10200Upcoming EarningsPositive NewsKMDAKamada3.8825 of 5 stars$6.39-1.7%$14.67+129.5%+23.9%$367.30M$160.95M22.82360Upcoming EarningsShort Interest ↓ALTAltimmune2.6578 of 5 stars$4.73+4.0%$20.83+340.5%-19.8%$364.28M$20,000.00-3.0550Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Revance Therapeutics Alternatives Maze Therapeutics Alternatives Mereo BioPharma Group Alternatives Zhengye Biotechnology Alternatives Zevra Therapeutics Alternatives Eton Pharmaceuticals Alternatives Rapport Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Kamada Alternatives Altimmune Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMUX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMUX Stock Free IMUX Stock Alerts